Expert Interview
A Third Look: Discussing the potential of Rezdiffra (resmetirom) for patients with MASH and the recently reported two-year results from the MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra.
Ticker(s): MDGLInstitution: Advocate Health Care
- Board certified Gastroenterologist for 10 years and Member of
- manages treatment for 65+ patients with CDI
- Familiar with the Phase 2a Clinical Trial data for Ibezapolstat
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
